Table 4.
Logistic regression calculating the odds ratios and 95% confidence interval of the association between period of diagnosis and likelihood of receiving a specific treatment, stratified by tumor subtype (group 1)
| Pre-COVID | Transition | Lockdown | Care restart | |
|---|---|---|---|---|
| HR+/HER2+ | ||||
| Neo-adjuvant chemotherapy | 1.10 (0.73–1.66) | 0.72 (0.39–1.32) | 2.85 (1.33–6.08) | 2.11 (1.32–3.38) |
| Neo-adjuvant endocrine therapya | 1.03 (0.47–2.28) | 2.56 (1.11–5.89) | 3.54 (1.64–7.60) | 1.13 (0.51–2.52) |
| Neo-adjuvant targeted therapyb | 0.93 (0.62–1.38) | 0.74 (0.41–1.34) | 2.77 (1.33–5.78) | 2.03 (1.29–3.20) |
| Mastectomy | 0.85 (0.60–1.22) | 1.37 (0.82–2.28) | 0.77 (0.43–1.37) | 1.09 (0.76–1.57) |
| Adjuvant chemotherapy | 1.27 (0.88–1.83) | 1.60 (0.94–2.73) | 0.58 (0.27–1.21) | 0.71 (0.46–1.10) |
| Adjuvant endocrine therapya | 0.81 (0.54–1.19) | 1.81 (0.88–3.73) | 1.04 (0.53–2.06) | 0.92 (0.60–1.42) |
| Adjuvant targeted therapyb | 1.34 (0.80–2.24) | 1.84 (0.85–4.01) | 1.53 (0.65–3.62) | 1.20 (0.68–2.10) |
| Adjuvant radiotherapy | 1.15 (0.76–1.73) | 0.73 (0.42–1.26) | 1.22 (0.61–2.41) | 0.86 (0.58–1.27) |
| IBR with autologous tissuec | 0.49 (0.07–3.73) | 1.79 (0.40–8.01) | NA | 1.35 (0.39–4.62) |
| IBR with implantc | 1.50 (0.76–2.97) | 0.83 (0.33–2.13) | 1.62 (0.53–4.94) | 1.27 (0.66–2.43) |
| IBR with autologous tissue and implantc | 1.90 (0.23–15.78) | NA | 8.02 (0.86–74.37) | NA |
| Chemotherapy after radiotherapyd | 1.00 (0.49–2.04) | 1.63 (0.49–5.44) | 4.30 (0.39–47.00) | 0.82 (0.33–2.00) |
| HR+/HER2− | ||||
| Neo-adjuvant chemotherapy | 0.83 (0.68–1.02) | 0.55 (0.41–0.75) | 1.21 (0.86–1.70) | 1.19 (0.96–1.46) |
| Neo-adjuvant endocrine therapya | 1.65 (1.35–2.02) | 3.10 (2.44–3.94) | 1.65 (1.15–2.37) | 1.38 (1.08–1.76) |
| Neo-adjuvant targeted therapyb | NA | NA | NA | NA |
| Mastectomy | 0.94 (0.82–1.07) | 1.06 (0.88–1.27) | 1.17 (0.93–1.49) | 1.33 (1.14–1.54) |
| Adjuvant chemotherapy | 1.00 (0.84–1.18) | 1.20 (0.95–1.52) | 1.08 (0.79–1.47) | 1.09 (0.90–1.33) |
| Adjuvant endocrine therapya | 0.99 (0.87–1.12) | 1.02 (0.84–1.24) | 1.05 (0.80–1.37) | 1.25 (1.05–1.48) |
| Adjuvant targeted therapyb | NA | NA | NA | NA |
| Adjuvant radiotherapy | 0.95 (0.83–1.07) | 0.96 (0.80–1.16) | 0.92 (0.72–1.17) | 0.81 (0.69–0.94) |
| IBR with autologous tissuec | 1.20 (0.69–2.10) | 0.35 (0.08–1.41) | 0.78 (0.24–2.48) | 2.38 (1.53–3.70) |
| IBR with implantc | 0.87 (0.67–1.13) | 0.97 (0.68–1.39) | 0.62 (0.38–0.99) | 1.19 (0.92–1.53) |
| IBR with autologous tissue and implantc | 0.20 (0.03–1.46) | 0.44 (0.06–3.17) | 0.67 (0.09–4.87) | 1.12 (0.44–2.81) |
| Chemotherapy after radiotherapyd | 2.60 (1.71–3.97) | 1.17 (0.72–1.91) | 1.21 (0.63–2.34) | 1.14 (0.77–1.67) |
| HR−/HER2+ | ||||
| Neo-adjuvant chemotherapy | 2.87 (1.28–6.44) | 0.78 (0.31–1.97) | 1.63 (0.55–4.82) | 1.66 (0.80–3.44) |
| Neo-adjuvant endocrine therapya | NA | NA | NA | NA |
| Neo-adjuvant targeted therapyb | 2.99 (1.34–6.68) | 0.82 (0.33–2.05) | 1.70 (0.58–5.01) | 1.75 (0.85–3.60) |
| Mastectomy | 0.79 (0.47–1.35) | 0.80 (0.38–1.67) | 0.81 (0.37–1.76) | 1.07 (0.64–1.79) |
| Adjuvant chemotherapy | 0.58 (0.28–1.21) | 1.11 (0.47–2.64) | 0.44 (0.14–1.42) | 0.62 (0.29–1.29) |
| Adjuvant endocrine therapya | NA | NA | NA | NA |
| Adjuvant targeted therapyb | 3.18 (0.98–10.30) | 0.77 (0.26–2.22) | 1.22 (0.31–4.80) | 0.74 (0.33–1.67) |
| Adjuvant radiotherapy | 1.51 (0.79–2.90) | 1.50 (0.60–3.75) | 0.95 (0.39–2.33) | 1.15 (0.63–2.10) |
| IBR with autologous tissuec | 2.62 (0.51–13.45) | NA | 2.38 (0.25–22.79) | 0.85 (0.10–7.14) |
| IBR with implantc | 0.40 (0.11–1.44) | 0.81 (0.16–4.16) | 0.45 (0.09–2.30) | 0.63 (0.22–1.77) |
| IBR with autologous tissue and implantc | NA | NA | NA | NA |
| Chemotherapy after radiotherapyd | 4.41 (0.43–45.48) | 2.82 (0.52–15.33) | NA | 0.27 (0.04–1.84) |
| HR−/HER2− | ||||
| Neo-adjuvant chemotherapy | 1.54 (1.07–2.21) | 0.46 (0.27–0.77) | 0.95 (0.50–1.81) | 2.49 (1.55–4.00) |
| Neo-adjuvant endocrine therapya | NA | NA | NA | NA |
| Neo-adjuvant targeted therapyb | NA | NA | NA | NA |
| Mastectomy | 1.02 (0.77–1.37) | 0.98 (0.62–1.54) | 0.78 (0.46–1.31) | 0.97 (0.69–1.35) |
| Adjuvant chemotherapy | 1.07 (0.80–1.42) | 2.87 (1.85–4.45) | 1.30 (0.80–2.11) | 1.25 (0.91–1.72) |
| Adjuvant endocrine therapya | NA | NA | NA | NA |
| Adjuvant targeted therapyb | NA | NA | NA | NA |
| Adjuvant radiotherapy | 0.74 (0.54–1.01) | 0.84 (0.52–1.37) | 2.64 (1.19–5.88) | 1.16 (0.78–1.73) |
| IBR with autologous tissuec | 0.49 (0.06–3.69) | NA | NA | 3.16 (1.15–8.68) |
| IBR with implantc | 1.00 (0.55–1.80) | 0.28 (0.08–1.03) | 0.49 (0.13–1.77) | 1.35 (0.73–2.50) |
| IBR with autologous tissue and implantc | NA | NA | 5.22 (0.59–46.13) | NA |
| Chemotherapy after radiotherapyd | 3.05 (1.20–7.71) | 3.18 (0.97–10.40) | 1.24 (0.41–3.73) | 1.27 (0.63–2.56) |
Reference 2018/2019; Pre-COVID: weeks 1–8, 2020; Transition: weeks 9–12, 2020; Lockdown: weeks 13–17, 2020; Care restart: weeks 18–26, 2020. Adjusted for age (< 50, 50–74, > 74) and stage
HER2 Human epidermal growth receptor 2, HR Hormone receptor, IBR Immediate breast reconstruction, NA Not applicable or too few patients for the analysis
aThese analyses only included patients with an HR+tumor
bThese analyses only included patients with an HER2+tumor
cThese analyses only included patients treated with a mastectomy
dThese analyses only included patients receiving adjuvant chemotherapy and radiotherapy. The likelihood of receiving chemotherapy after radiotherapy was compared with having radiotherapy after chemotherapy